Showing results (421-430 of 428) with videos related to

Sort By:
Pageof 43
You have reached the last page of results.This site can display upto 428 results.
Nature Communications|August 19, 2025
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinomaAmin H Nassar, Chul Kim, Tolulope Adeyelu, et al.
The Lancet. Oncology|November 6, 2021
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry studyDavid J Pinato, Josep Tabernero, Mark Bower, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) ConsortiumTalal El Zarif, Amin H Nassar, Elio Adib, et al.
JHEP Reports : Innovation in Hepatology|March 1, 2021
Assessing the impact of COVID-19 on liver cancer management (CERO-19)Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, et al.
Liver Cancer|October 9, 2025
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse StudyAlessandro Vitale, Jung Sun Kim, Giuseppe Cabibbo, et al.
Nature|March 25, 2021
NASH limits anti-tumour surveillance in immunotherapy-treated HCCDominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.
Journal for Immunotherapy of Cancer|February 4, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registryAlessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, et al.
Journal for Immunotherapy of Cancer|September 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registryAlessio Cortellini, Valentina Santo, Leonardo Brunetti, et al.
Pageof 43